Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB01-3
- Development stage
- Preclinical
- Lead developer
- Twist Bioscience
- Modality
- Antibody-Based Therapeutics
01
Overview
TB01-3 is a preclinical **GLP-1 receptor antagonist antibody** identified from Twist Bioscience's synthetic GPCR-focused antibody discovery platform. It is designed to bind **glucagon-like peptide 1 receptor** and block GLP-1 signaling, with in vivo data showing elevation of blood glucose in insulin-challenged mice, consistent with antagonism of incretin biology. Based on the available public information, TB01-3 appears to be an experimental antibody investigated for metabolic indications where transient GLP-1R blockade may be useful, such as hypoglycemia-related settings and management of effects associated with GLP-1 pathway activation; no approved commercial use has been identified.
02
Targets
Beyond the preview
Go deeper on TB01-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB01-3.